IL-22/IL-22R1 pathway enhances cholangiocarcinoma progression via ERK1/2 activation

Figure 4 Results of transcriptomic sequencing and public database analysis. A and B: GO enrichment analysis results of RNA-seq analysis; C and D: KEGG enrichment analysis results of RNA-seq analysis; E: Comparison of protein expression levels and quantitative analysis of p-ERK1/2, p-STAT3, BAX, and Bcl2 in HuCCT1 and RBE cells treated with IL-22 vs negative control group. ^aP < 0.05, ^bP < 0.01, ^cP < 0.001. NC: Negative control.